Related stories
Blackstone, Pfizer Partner to Fund Obesity Drug Development
Blackstone will provide up to $1.5 billion to fund Pfizer’s obesity drug development.
M impact | EQUITY | Nov 11, 2026, 09:43 PM UTC
Aristocrat Leisure Raises Annual Dividend; CEO to Retire in April
Aristocrat Leisure says CEO Trevor Croker intends to retire in April and names Dafne Guisard as incoming CEO. The company also raises its annual dividend.
M impact | EQUITY | Nov 11, 2026, 09:43 PM UTC
CAE Q2 Revenue Misses Estimates; FY Adjusted EPS Outlook Raised
Canada's CAE reported Q2 revenue below estimates and raised its full-year adjusted EPS outlook.
M impact | EQUITY | Nov 11, 2026, 09:41 PM UTC
Nasdaq Panel Determines to Delist NextNRG Stock
NextNRG said a Nasdaq Hearings Panel determined to delist its stock.
M impact | EQUITY | Nov 11, 2026, 09:38 PM UTC
Pfizer secures up to $1.5 billion from Blackstone for obesity drug development
M impact | EQUITY | Nov 11, 2026, 09:38 PM UTC
Eneva Board Approves Up to R$ 1.6 Billion in Financing for Two Power Plants
M impact | EQUITY | Nov 11, 2026, 09:38 PM UTC